BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 8966391)

  • 1. [Busulfan versus busulfan-interferon as maintenance therapy in chronic myeloid leukemia].
    López Hernández MA; Flores-Chapa JD; Trueba Christy E; Borbolla Escoboza JR; Carrillo Rosales T
    Rev Invest Clin; 1996; 48(4):281-7. PubMed ID: 8966391
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Treatment of chronic myeloid leukemia with interferon-alpha].
    Szomor A; Molnár L; Nagy A; Dávid M; Alizadeh H; Kecskés M; Vidra T; Kereskai L; Pajor L; Losonczy H
    Orv Hetil; 2000 Nov; 141(48):2601-4. PubMed ID: 11141958
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Multicenter prospective study of interferon-alpha and conventional chemotherapy versus bone marrow transplantation for newly diagnosed patients with chronic myelogenous leukemia. Kouseisho Leukemia Study Group.
    Ohnishi K; Minami S; Ueda T; Nishimura M; Tsubaki K; Takemoto Y; Takeshita A; Sao H; Kageyama S; Ueda R; Ohno R
    Int J Hematol; 2000 Aug; 72(2):229-36. PubMed ID: 11039674
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Alpha-interferon with very-low-dose donor lymphocyte infusion for hematologic or cytogenetic relapse of chronic myeloid leukemia induces rapid and durable complete remissions and is associated with acceptable graft-versus-host disease.
    Posthuma EF; Marijt EW; Barge RM; van Soest RA; Baas IO; Starrenburg CW; van Zelderen-Bhola SL; Fibbe WE; Smit WM; Willemze R; Falkenburg JH
    Biol Blood Marrow Transplant; 2004 Mar; 10(3):204-12. PubMed ID: 14993886
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Effects of chemotherapy (busulfan-hydroxyurea) and interferon-alfa on bone marrow morphologic features in chronic myelogenous leukemia. Histochemical and morphometric study on sequential trephine biopsy specimens with special emphasis on dynamic features.
    Thiele J; Kvasnicka HM; Schmitt-Graeff A; Bundschuh S; Biermann T; Roessler G; Wasmus M; Diehl V; Zankovich R; Schaefer HE
    Am J Clin Pathol; 2000 Jul; 114(1):57-65. PubMed ID: 10884800
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Interferon-alpha in the treatment of patients with chronic myeloid leukemia].
    Faber E; Jarosová M; Divoký V; Luhový M; Komenda S; Sulovská I; Hubácek J; Slezák P; Papajik T; Raida L; Heczko M; Indrák K
    Vnitr Lek; 1997 Jan; 43(1):13-7. PubMed ID: 9221559
    [TBL] [Abstract][Full Text] [Related]  

  • 7. [Interferon in the eradication of the Philadelphia chromosome in chronic myeloid leukemia].
    Arana-Trejo RM; Ovilla-Martínez R; Gómez-Morales E; Meillon-García L; Cervantes-Peredo A; González-Llaven J; Pizzuto-Chávez J; Kofman-Alfaro S
    Rev Invest Clin; 1997; 49(3):209-14. PubMed ID: 9380976
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Alpha-interferons in the treatment of patients with chronic myeloid leukemia].
    Abdulkadyrov KM; Udal'eva VIu; Rukavitsyn OA; Bessmel'tsev SS
    Vopr Onkol; 1999; 45(4):387-92. PubMed ID: 10532097
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Comparative efficiency of conventional myelosuppressive chemotherapy and therapy including interferon alpha in patients with chronic myeloid leukemia].
    Volkova SA; Prytkova MV; Borovkov NN
    Klin Med (Mosk); 2004; 82(3):45-50. PubMed ID: 15114775
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Interferon alpha--the drug of choice for patients with chronic myeloid leukemia].
    Klamová H; Vítek A; Michalová K; Brezinová J; Moravcová J; Jelínek J; Cermák J
    Cas Lek Cesk; 1998 Sep; 137(18):552-6. PubMed ID: 9818464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [A trial for prolongation of chronic phase of chronic myeloid leukemia--maintenance of leukocyte counts within normal range with busulfan].
    Matsuo T; Tomonaga M; Kuriyama K; Jinnai I; Jubashi T; Nonaka H; Kohno T; Tsukasaki K; Atogami S; Itoyama T
    Rinsho Ketsueki; 1989 May; 30(5):625-30. PubMed ID: 2795875
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [The effectiveness of interferon-alpha therapy in Ph-positive chronic myeloid leukemia].
    Bogdanov KV; Frolova OI; Marinets OV; Ogorodnikova IuS; Afanas'ev BV; Zaritskiĭ AIu
    Vopr Onkol; 2003; 49(2):189-92. PubMed ID: 12785203
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Interferon-alpha in the treatment of chronic myeloid leukemia].
    Guilhot F
    Rev Prat; 1999 Mar; 49(5):464-6. PubMed ID: 10358394
    [No Abstract]   [Full Text] [Related]  

  • 14. [Occurrence of autoimmune complications in patients with chronic myelocytic leukemia during treatment with interferon alfa].
    Tóthová E; Stecová N; Kafková A; Fricová M; Svorcová E
    Vnitr Lek; 2002 May; 48(5):380-3. PubMed ID: 12061203
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interferon alfa versus chemotherapy for chronic myeloid leukemia: a meta-analysis of seven randomized trials: Chronic Myeloid Leukemia Trialists' Collaborative Group.
    J Natl Cancer Inst; 1997 Nov; 89(21):1616-20. PubMed ID: 9362160
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [The analysis of failures in the treatment of children with chronic myelocytic leukemia in the studies of Polish pediatric leukemia/ lymphoma group].
    Chybicka A; Bogusławska-Jaworska J; Kałwak K; Turkiewicz D; Armata J; Balcerska A; Cwiklińska M; Hicke-Roberts A; Kaczmarek-Kanold M; Kołecki P; Kowalczyk J; Krauze A; Matysiak M; Płoszyńska A; Rokicka-Milewska R; Sońta-Jakimczyk D; Sikorska-Fic B; Wiśniewska-Slusarz H; Wysocki M; Wachowiak J
    Wiad Lek; 1998; 51 Suppl 4():33-9. PubMed ID: 10731941
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized study of intermediate as compared with high doses of interferon-alpha for chronic myeloid leukemia: no differences in cytogenetic responses.
    Peñarrubia MJ; Odriozola J; González C; Massagué I; Miguel A; González San Miguel JD; Pérez Encinas M; Lavilla E; Giraldo MP; Casado LF; Ferrer S; Steegmann JL;
    Ann Hematol; 2003 Dec; 82(12):750-8. PubMed ID: 14517691
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prolonged chronic phase in chronic myelogenous leukemia after homoharringtonine therapy.
    Li YF; Deng ZK; Xuan HB; Zhu JB; Ding BH; Liu XN; Chen BA
    Chin Med J (Engl); 2009 Jun; 122(12):1413-7. PubMed ID: 19567163
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Results of imatinib therapy in late-stage chronic myeloid leukemia after treatment with interferon-alpha].
    Molnár L; Nagy A; Dávid M; Szomor A; Méhes G; Kovács G; Losonczy H
    Orv Hetil; 2004 Apr; 145(17):901-7. PubMed ID: 15170967
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Fluctuating molecular remission in patients with chronic myeloid leukemia with long term complete cytogenetic response after alpha interferon treatment].
    Casado LF; Picó M; Gómez C; Ferro MT; Fernández-Rañada JM; Steegmann JL
    Med Clin (Barc); 1997 Sep; 109(7):251-5. PubMed ID: 9333689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.